Merck to acquire Caraway Therapeutics in $610m deal for neurodegenerative disease treatments
Merck and Caraway Therapeutics, Inc. have announced a definitive agreement in which Merck, through a subsidiary, will acquire Caraway Therapeutics. The total potential consideration for the acquisition is up to $610 million, including an undisclosed upfront payment and contingent milestone payments. Expanding Research in Neurodegenerative Diseases This acquisition aligns with Merck’s commitment to enhancing its […]